Research reveals enhanced circularly polarized luminescence in helicrates, suggesting new applications for drug recognition.
The development of circularly polarized luminescence (CPL) emitters with a luminescence dissymmetry factor (|glum|) approaching the theoretical limit of 2 remains a central challenge in chiral photonics. Herein, considerable glum values (1.48-1.65) were achieved in helicates (NMe₄)₂[Eu₂(R/S-L¹⁻⁴)₄] (ΔΔ/ΛΛ-1-4) with different structural rigidity, as well as in crown ether-modified (NMe₄)₂[Eu₂(R/S-L⁵)₄] (ΔΔ/ΛΛ-5) that exhibits adjustable coordination geometry symmetry. Notably, encapsulating bulkier [NEt₄]⁺ instead of a [NMe₄]⁺ counterion within the inner cavity of ΔΔ/ΛΛ-2 further elevates |glum| to an unprecedented 1.71, the highest value for any chiral molecular emitter. While the NMe₄-ΔΔ/ΛΛ-3 achieves an ultrahigh CPL brightness (BCPL = 3625 M⁻¹ cm⁻¹), resulting from its large glum value (1.63) and high quantum yield (ΦPL = 32%). Structural and spectroscopic analyses demonstrate that the high CPL activity originates from a conformationally rigidified square antiprismatic (SAP) geometry around the Eu(III) center. This structure and property relationship is vividly demonstrated by the crown-ether-functionalized ΔΔ-5, where gradual binding of Cs⁺ ions triggers a pronounced glum fluctuation (1.48 → 0.62 → 1.41) through a perturbation and subsequent restoration of the SAP environment. Furthermore, the multicrown-ether binding sites in ΔΔ-5 enable cooperative guest binding, facilitating the first naked-eye CPL recognition of the antispasmodic drug tizanidine. This work establishes rigidifying SAP configuration as a general design principle for maximizing the CPL activity of lanthanide complexes and opening avenues for advanced CPL applications.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: